Clinical Trials

419 enrolled 10 charts

Multiple Myeloma

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma

NCT05050097 2026-03-13

MonumenTAL-2

166 enrolled

Multiple Myeloma

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

52 enrolled

Multiple Myeloma

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

15 enrolled

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT05556798 2026-02-24

A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment

9 enrolled

Multiple Myeloma

NCT02659930 2026-02-19

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

62 enrolled

Sarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT04162210 2026-02-11

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

MyeloidOther hematologic neoplasm

50 enrolled 12 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

5 enrolled

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

117 enrolled

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

208 enrolled

Multiple Myeloma

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

6 enrolled

Multiple Myeloma, Recurrence

NCT04302324 2025-10-01

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

9 enrolled

Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

14 enrolled

Multiple Myeloma

NCT04124497 2025-08-08

DPd

45 enrolled

Chromosome 17 deletion, Multiple Myeloma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT02719613 2025-06-05

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

67 enrolled

Phase NA Active not recruiting

Multiple Myeloma

NCT06924424 2025-04-11

Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

105 enrolled

Multiple Myeloma, Neoplasms

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT04667663 2025-01-09

CPD-DARA

16 enrolled

Multiple Myeloma

NCT02406222 2024-12-05

MUKseven

124 enrolled

Multiple Myeloma, Recurrence

NCT02542657 2024-09-19

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

30 enrolled

Neoplasms, Plasma Cell

NCT03651128 2022-12-15

KarMMa-3

381 enrolled